SCHEMBL4986221

SCHEMBL4986221

O=C(O)c1cccn(Cc2ccccc2-c2ccc(F)cc2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.49
TP53 P04637 3/20 0.46
RXFP1 Q9HBX9 3/20 0.46
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
BRD4 O60885 2/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
BRDT Q58F21 1/20 0.43
KCNA5 P22460 1/20 0.43
KCNH2 Q12809 1/20 0.43
MAPT P10636 2/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4986527 0.92 BRD4 (0.47) TP53RXFP1LMNASMN1; SMN2KMT2A
SCHEMBL4996274 0.85 PTGER3 (0.43) TP53RXFP1LMNASMN1; SMN2BRD4
SCHEMBL4994050 0.85 SLC6A3 (0.60) LIPGTP53RXFP1LMNASMN1; SMN2
SCHEMBL4994721 0.84 CYP1A2 (0.44) TP53RXFP1LMNASMN1; SMN2BRD4
SCHEMBL2621620 0.79 CNR1 (0.60) LMNASMN1; SMN2MEN1KMT2AHTT
SCHEMBL4553891 0.79 MCL1 (0.49) TP53RXFP1LMNASMN1; SMN2MEN1
SCHEMBL4438770 0.79 MAPT (0.53) TP53RXFP1LMNASMN1; SMN2MEN1
SCHEMBL4992971 0.78 PTGER3 (0.48) TP53RXFP1LMNABRD4BRD2
SCHEMBL4996102 0.78 BRD4 (0.44) TP53RXFP1LMNASMN1; SMN2HTT
SCHEMBL4994006 0.77 HDAC3 (0.56) TP53RXFP1LMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 LIPG 1889/4885TP53 3536/4885RXFP1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.